Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 451 participants.

Also called NCT01517412

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 451 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01517412
  • EudraCT 2011-002416-85
Other papers using this trial's data
  • Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day Journal of diabetes and its complications, 2014 DOI, PubMed 25012990

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, France, Germany, Poland, Romania, Russia, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01517412. Randomized; no masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2016-10-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Lixisenatide (AVE0010)
Intervention (Device)
Self-injector pen device (OptiClik®)
Intervention (Drug)
Metformin
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01517412
Content hash
58b8f45ff8fde0207d04fd602cd487c937464f331051722dd05e99b0538f7ff4